Navigation Links
Rigel Announces First Quarter 2012 Financial Results
Date:5/1/2012

coid lupus in the next few months," said James M. Gower, chairman and chief executive officer of Rigel.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include: fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with Rigel's collaboration partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy, the potential uses and efficacy of Rigel's product candidates, the progress of Rigel's product development programs, including the timing of commencement and results thereof, the timing and design of its future clinical trials and potential milestones and regulatory filings associated with Rigel's product candidates, Rigel's corporate collaborations, and revenues that may be received from collaborations and the timing of those potential payments, and the future expected amount and sufficiency of Rigel's cash resources. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as  "plan," "expect,"
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Pa., Sept. 9 DeVilbiss Healthcare has selected Business ... the successful implementation of its Microsoft Dynamics AX solution. ... Sunrise Medical, DeVilbiss sought to select and implement a ... successful medical device manufacturer. The primary ...
... Sept. 9 Diplomat Specialty Pharmacy announced today they have earned ... ranking of the fastest-growing private companies in America. "We,re ... earning a position of 554 in the nation, but if you ... are even more remarkable," stated Phil Hagerman, President and CEO of ...
Cached Medicine Technology:Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare 2Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:7/11/2014)... 2014 The American Association of Poison ... centers are commending Senator Bill Nelson (D-FL) for his ... 2014 on July 10, 2014. Along with fellow Senate ... Commission (CPSC) to enact rules requiring safer, child-resistant packaging ... , Senate co-sponsors of the bill include: Sen. Richard ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... News) -- People with the lowest incomes may have a ... (PAD), a new study suggests. People with PAD have ... most often the legs. The condition causes leg pain and ... the body. People with PAD have a higher risk for ... 6,800 people with PAD who took part in the U.S. ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
... testing breast tumors for HER2 ( http://www.mayoclinic.com/health/breast-cancer/AN00495 ) proteins ... of tumor (a single tumor block) is analyzed. However, ... ( http://www.mayoclinic.org/ ) found that HER2 results can vary ... tumor blocks are analyzed. This could have significant ...
... News) -- Americans who live in walkable neighborhoods are ... a higher quality of life, a new study suggests. ... stroll to such destinations as parks and playgrounds, club ... coffee shops and restaurants, explained study author Shannon Rogers ...
... from a specialized scan, radiation oncologists at Mayo Clinic ... number of lymph nodes critical for removing fluid from ... VIDEO ALERT: Additional audio and video resources, including excerpts ... researchers presenting at San Antonio Breast Cancer Symposium, are ...
... GeparQuinto study, randomized Phase III efficacy data on the ... early breast cancer will be presented at the 33rd ... von Minckwitz, M.D., Ph.D., managing director of the German ... efficacy data from this study, which will detail the ...
... Dec. 10 (HealthDay News) -- Children and teens accounted for ... treated in U.S. emergency departments between 1997 and 2006, a ... such heat-related injuries also increased 133 percent during the study ... according to the researchers at the Center for Injury Research ...
... of circulating tumor cells (CTCs) cells that have detached ... the blood are an independent prognostic marker in metastatic ... CTC level during therapy was found to be an early ... series validating the prognostic value of CTCs in first-line chemotherapy ...
Cached Medicine News:Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 2Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 3Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 4Health News:'Walkable' Communities More Close-Knit, Study Finds 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented 2Health News:Children, Teens Account for Half of Exercise-Related Heat Injuries 2Health News:High CTC levels predicted poor outcome in metastatic breast cancer 2
Sub Pectoral Bra...
Bandeau Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
Medicine Products: